ABOS
Acumen Pharmaceuticals, Inc.
There isn't enough reported data to score ABOS yet.
ABOS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ABOS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ABOS PE Valuation
ABOS has no meaningful PE right now: it lost money over the past year.
ABOS Forward outlook
There aren't enough analyst estimates for ABOS to show an outlook.
ABOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.53 | +$0.69 |
| Q2 2026 | -$1.62 | +$0.66 |
| Q1 2026 | -$1.85 | +$0.09 |
| Q4 2025 | -$2.00 | -$0.29 |
| Q3 2025 | -$2.22 | -$0.85 |
| Q2 2025 | -$2.28 | -$1.17 |
| Q1 2025 | -$1.94 | -$0.89 |
| Q4 2024 | -$1.71 | -$0.63 |
ABOS is still losing money, but less than at its worst: $1.53 per share over the past year, against $2.28 at its worst in mid-2025.
ABOS Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2020 | -408% | N/A |
| Q3 2020 | -341% | N/A |
| Q2 2020 | -1348% | N/A |
| Q1 2020 | -905% | N/A |
ABOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.7M | +$3.8M |
| Q2 2026 | -$18.1M | +$13.8M |
| Q1 2026 | -$24.1M | +$10.1M |
| Q4 2025 | -$19.1M | +$8.1M |
| Q3 2025 | -$30.5M | -$5.9M |
| Q2 2025 | -$31.8M | -$15.3M |
| Q1 2025 | -$34.2M | -$16.3M |
| Q4 2024 | -$27.2M | -$18.9M |
ABOS has burned cash in almost every quarter: −$88M over the past year, against −$124M the year before.
ABOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +70.8K shares |
| 1 year | +19% | +11.7M shares |
| 3 years | +33% | +18.1M shares |
| 5 years | +16628% | +71.9M shares |
ABOS has 72M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABOS Net Leverage
ABOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ABOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.9 | Oversold |
| Stochastic | 0.6 | Oversold |
ABOS's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
ABOS PE vs Healthcare Sector
ABOS has no meaningful PE right now: it lost money over the past year.
ABOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.34 | 84% below |
| 20 week MA | $2.13 | 90% below |
| 50 week MA | $2.31 | 90% below |
| 100 week MA | $1.87 | 88% below |
| 200 week MA | $2.88 | 92% below |
ABOS is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
ABOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $20.3 | $7.07 | -65% |
| 2022 | $7.07 | $5.21 | -26% |
| 2023 | $5.21 | $3.84 | -26% |
| 2024 | $3.84 | $1.78 | -54% |
| 2025 | $1.78 | $2.11 | +19% |
| 2026 YTD | $2.11 | $0.22 | -90% |
ABOS has finished lower in four of the last five years. It's down 90% so far in 2026.